Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016 (2016), Article ID 2930414, 8 pages
http://dx.doi.org/10.1155/2016/2930414
Clinical Study

Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

1Department of Medical Sciences, University of Turin, Turin, Italy
2Oncological Endocrinology, A.O.U. “Città della Salute e della Scienza di Torino” Hospital, Turin, Italy
3Transition Unit for Childhood Cancer Survivors, A.O.U. “Città della Salute e della Scienza di Torino” Hospital, Turin, Italy
4Department of Drug Science and Technology, University of Turin, Turin, Italy
5Section of Endocrinology, Division of Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
6Endocrinology, Diabetes, and Metabolism Unit, A.O. Ordine Mauriziano di Torino, “Umberto I” Hospital, Turin, Italy

Received 30 June 2016; Accepted 8 September 2016

Academic Editor: Carlo Cappelli

Copyright © 2016 Maria Graziella Catalano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. McIver, I. D. Hay, D. F. Giuffrida et al., “Anaplastic thyroid carcinoma: a 50-year experience at a single institution,” Surgery, vol. 130, no. 6, pp. 1028–1034, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Kim and R. D. Leeper, “Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy,” Cancer, vol. 60, no. 10, pp. 2372–2375, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Sherman, S. H. Lim, A. L. Ho et al., “Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review,” Radiotherapy and Oncology, vol. 101, no. 3, pp. 425–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. I. Haddad, W. M. Lydiatt, D. W. Ball et al., “Anaplastic thyroid carcinoma, version 2.2015,” Journal of the National Comprehensive Cancer Network, vol. 13, no. 9, pp. 1140–1150, 2015. View at Google Scholar
  5. K. B. Ain, “Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches,” Thyroid, vol. 8, no. 8, pp. 715–726, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Higashiyama, Y. Ito, M. Hirokawa et al., “Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma,” Thyroid, vol. 20, no. 1, pp. 7–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Kawada, K. Kitagawa, S. Kamei et al., “The feasibility study of docetaxel in patients with anaplastic thyroid cancer,” Japanese Journal of Clinical Oncology, vol. 40, no. 6, Article ID hyq025, pp. 596–599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Nagaiah, A. Hossain, C. J. Mooney, J. Parmentier, and S. C. Remick, “Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment,” Journal of Oncology, vol. 2011, Article ID 542358, 13 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Savvides, G. Nagaiah, P. Lavertu et al., “Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid,” Thyroid, vol. 23, no. 5, pp. 600–604, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Bose, Y. Dai, and S. Grant, “Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights,” Pharmacology and Therapeutics, vol. 143, no. 3, pp. 323–336, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. Q.-T. Luong, J. O'Kelly, G.-D. Braunstein, J.-M. Hershman, and H.-P. Koeffler, “Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo,” Clinical Cancer Research, vol. 12, no. 18, pp. 5570–5577, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-A. Woyach, R.-T. Kloos, M.-D. Ringel et al., “Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 1, pp. 164–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-F. Lin, J.-D. Lin, T.-C. Chou, Y.-Y. Huang, and R. J. Wong, “Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment,” PLoS ONE, vol. 8, no. 10, Article ID e77684, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M.-G. Catalano, M. Pugliese, E. Gargantini et al., “Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo,” International Journal of Cancer, vol. 130, no. 3, pp. 694–704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. G. Catalano, N. Fortunati, M. Pugliese et al., “Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 7, pp. E1150–E1159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Pugliese, N. Fortunati, A. Germano et al., “Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells,” Thyroid, vol. 23, no. 7, pp. 838–846, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. E. S. Grassi, V. Vezzoli, I. Negri et al., “SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways,” Oncotarget, vol. 6, no. 34, pp. 36383–36399, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. M. G. Catalano, N. Fortunati, M. Pugliese et al., “Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells,” The Journal of Endocrinology, vol. 191, no. 2, pp. 465–472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. G. Catalano, R. Poli, M. Pugliese, N. Fortunati, and G. Boccuzzi, “Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 839–845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Airoldi, L. Cattel, P. Milla, F. Pedani, M. Garzaro, and F. Dosio, “Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions,” Anticancer Research, vol. 28, no. 4, pp. 2519–2527, 2008. View at Google Scholar · View at Scopus
  21. R.-C. Smallridge and J.-A. Copland, “Anaplastic thyroid carcinoma: pathogenesis and emerging therapies,” Clinical Oncology, vol. 22, no. 6, pp. 486–497, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Granata, R. Locati, and R. Licitra, “Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature,” Current Opinion in Oncology, vol. 25, no. 3, pp. 224–228, 2013. View at Google Scholar
  23. R. C. Smallridge, K. B. Ain, S. L. Asa et al., “American thyroid association guidelines for management of patients with anaplastic thyroid cancer,” Thyroid, vol. 22, no. 11, pp. 1104–1139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Brignardello, N. Palestini, F. Felicetti et al., “Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012,” Thyroid, vol. 24, no. 11, pp. 1600–1606, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Göttlicher, S. Minucci, P. Zhu et al., “Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells,” The EMBO Journal, vol. 20, no. 24, pp. 6969–6978, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. C.-J. Phiel, F. Zhang, E.-Y. Huang, M.-G. Guenther, M.-A. Lazar, and P.-S. Klein, “Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen,” The Journal of Biological Chemistry, vol. 276, no. 39, pp. 36734–36741, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Zhang, N. Li, C. Caron et al., “HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo,” The EMBO Journal, vol. 22, no. 5, pp. 1168–1179, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Jordan and L. Wilson, “Microtubules as a target for anticancer drugs,” Nature Reviews Cancer, vol. 4, no. 4, pp. 253–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Arce, C. Pérez-Plasencia, A. González-Fierro et al., “A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer,” PLoS ONE, vol. 1, no. 1, article e98, 2006. View at Publisher · View at Google Scholar
  30. P. Münster, D. Marchion, E. Bicaku et al., “Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1979–1985, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Garcia-Manero, H. Yang, C. Bueso-Ramos et al., “Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes,” Blood, vol. 111, no. 3, pp. 1060–1066, 2008. View at Google Scholar
  32. C. J. Mooney, G. Nagaiah, P. Fu et al., “A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome,” Thyroid, vol. 19, no. 3, pp. 233–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-A. Sosa, R. Elisei, B. Jarzab et al., “Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma,” Thyroid, vol. 24, no. 2, pp. 232–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. M.-M. Cooney, P. Savvides, S. Agarwala et al., “Phase II study of combretastatinA4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC),” Journal of Clinical Oncology, vol. 24, no. 18S, p. A5580, 2006. View at Google Scholar
  35. K. C. Bible, V. J. Suman, M. E. Menefee et al., “A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. 3179–3184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Y.-L. Yap, W. K. Chui, and A. Chan, “Drug interactions between chemotherapeutic regimens and antiepileptics,” Clinical Therapeutics, vol. 30, no. 8, pp. 1385–1407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Wen, J.-S. Wang, K.-T. Kivistö, P.-J. Neuvonen, and J.-T. Backman, “In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9),” British Journal of Clinical Pharmacology, vol. 52, no. 5, pp. 547–553, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Eyal, J. G. Lamb, M. Smith-Yockman et al., “The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver,” British Journal of Pharmacology, vol. 149, no. 3, pp. 250–260, 2006. View at Publisher · View at Google Scholar · View at Scopus